Skip to main content
SteadySharesSteadySharesSteadyStShares
The market
MarketsDiscover
Follow the money
Super InvestorsPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in to save your work
Open
SteadySharesMarketsDiscoverSuper InvestorsMy WealthPoliticiansCryptoNews
DiscoverTRIB
HealthcareNMSUSD

Trinity Biotech plc

$00123456789.0012345678900123456789+2263.9%
52w low (est.) $6.72$10.81 52w high (est.)
Market data · updated 51m ago
Market data
Market cap
USD5.70M
52w range
USD7.94 - USD103.20
Beta
1.00
Sector
Healthcare
Data quality
54/100
Valuation
PEG ratio
0.30
Quality & efficiency
Moat score
19/100
Profit margin
-85.4%
Run the 10-point checklist before you buy How these numbers are made

About Trinity Biotech plc

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. In addition, the company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. It has a collaboration agreement with a bioinformatics company to conduct analysis on clinical trial data for EpiCapture, a molecular diagnostics company for developing a non invasive urine based prognostic test for progression to aggressive prostate cancer. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

Valuation

ValueGrowthProfitHealthIncome23QUALITY
Overall Rating
31
Reduce
Reduce

Derived from filed metrics · Moderate confidence (54% of the inputs available)

Moat Score19
DCF Intrinsic Value
Not covered by our valuation model yet.

Moat, DCF and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
USD5.70M
P/E Ratio
N/A
Dividend Yield
0.00%
Revenue Growth
0.0%
Profit Margin
-85.4%
ROE
0.0%
Debt / Equity
0.00
Beta
1.00
Beaten Down
vs Healthcare sector:Moat 19 vs 7Yield 0.00% vs 0.3%

Statistics

Similar Stocks · Healthcare

LLY73
$920.00+0.7%
AZN.L72
£105.20+0.6%
UNH71
$492.10+1.6%
JNJ70
$146.20-0.2%

Latest News · TRIB